携带 FBXW7 突变的肺腺癌患者使用替西罗莫司治疗。
Temsirolimus therapy in a patient with lung adenocarcinoma harboring an FBXW7 mutation.
机构信息
University of Pittsburgh Cancer Institute, University of Pittsburgh, School of Medicine/Hematology-Oncology, Lung and Thoracic Malignancies Program, Pittsburgh, PA 15232, United States.
University of Pittsburgh Cancer Institute, University of Pittsburgh, School of Medicine/Hematology-Oncology, Lung and Thoracic Malignancies Program, Pittsburgh, PA 15232, United States.
出版信息
Lung Cancer. 2014 Feb;83(2):300-1. doi: 10.1016/j.lungcan.2013.11.018. Epub 2013 Dec 1.
Abstract
We report the identification of an FBXW7 mutation in a patient with adenocarcinoma of the lung, whose tumor had previously been shown to be EGFR and ALK wild type and who had previously progressed on multiple lines of systemic therapy. She experienced both clinical and radiographic benefit from treatment with the mTOR inhibitor temsirolimus.
摘要
我们报告了一例肺腺癌患者 FBXW7 突变的鉴定，该患者的肿瘤先前被证实为 EGFR 和 ALK 野生型，并且先前已经接受了多线系统治疗。她接受 mTOR 抑制剂替西罗莫司治疗后，既获得了临床获益，也获得了影像学获益。
相似文献
1
Temsirolimus therapy in a patient with lung adenocarcinoma harboring an FBXW7 mutation.携带 FBXW7 突变的肺腺癌患者使用替西罗莫司治疗。
Lung Cancer. 2014 Feb;83(2):300-1. doi: 10.1016/j.lungcan.2013.11.018. Epub 2013 Dec 1.
2
FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.FBXW7靶向mTOR进行降解，并在肿瘤抑制中与PTEN协同作用。
Science. 2008 Sep 12;321(5895):1499-502. doi: 10.1126/science.1162981.
3
Subacute cutaneous lupus erythematosus associated with pemetrexed plus Carboplatin chemotherapy.与培美曲塞联合卡铂化疗相关的亚急性皮肤型红斑狼疮
J Clin Rheumatol. 2014 Dec;20(8):449-50. doi: 10.1097/RHU.0000000000000183.
4
Identification of molecular targets in vulvar cancers.外阴癌分子靶点的鉴定
Gynecol Oncol. 2017 Aug;146(2):305-313. doi: 10.1016/j.ygyno.2017.05.011. Epub 2017 May 20.
5
Rapamycin inhibits FBXW7 loss-induced epithelial-mesenchymal transition and cancer stem cell-like characteristics in colorectal cancer cells.雷帕霉素抑制 FBXW7 缺失诱导的结直肠癌细胞上皮-间充质转化和癌症干细胞样特征。
Biochem Biophys Res Commun. 2013 May 3;434(2):352-6. doi: 10.1016/j.bbrc.2013.03.077. Epub 2013 Apr 2.
6
Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations.LUX-Lung 3 研究：阿法替尼或顺铂/培美曲塞治疗伴有 EGFR 突变的晚期肺腺癌患者的 III 期研究：症状控制和生活质量。
J Clin Oncol. 2013 Sep 20;31(27):3342-50. doi: 10.1200/JCO.2012.46.1764. Epub 2013 Jul 1.
7
A Case of Hepatic Portal Venous Gas in a Patient Treated with Pemetrexed and Carboplatin for Lung Cancer.培美曲塞和顺铂治疗肺癌患者发生肝门静脉气体一例。
Chemotherapy. 2014;60(2):88-90. doi: 10.1159/000371440.
8
Clinical response to crizotinib retreatment after acquisition of drug resistance.获得耐药性后对克唑替尼再治疗的临床反应。
J Clin Oncol. 2013 Jul 1;31(19):e322-3. doi: 10.1200/JCO.2012.46.4305. Epub 2013 May 28.
9
Complete radiological response of metastatic anaplastic lymphoma kinase-positive signet ring lung adenocarcinoma to systemic chemotherapy.转移性间变性淋巴瘤激酶阳性印戒样肺腺癌对全身化疗的完全放射学缓解
J Thorac Oncol. 2011 May;6(5):963-5. doi: 10.1097/JTO.0b013e318215a242.
10
Concomitant chemoradiotherapy using pemetrexed and carboplatin for unresectable stage III non-small cell lung cancer (NSCLC): preliminary results of a phase II study.培美曲塞联合卡铂同期放化疗治疗不可切除的 III 期非小细胞肺癌（NSCLC）：一项 II 期研究的初步结果。
Lung Cancer. 2011 Jun;72(3):327-32. doi: 10.1016/j.lungcan.2010.09.012. Epub 2010 Nov 5.
引用本文的文献
1
Clinical significance of FBXW7 loss of function in human cancers.FBXW7 功能丧失在人类癌症中的临床意义。
Mol Cancer. 2022 Mar 26;21(1):87. doi: 10.1186/s12943-022-01548-2.
2
Complex genetic alterations contribute to rapid disease progression in an rearrangement lung adenocarcinoma patient: a case report.复杂基因改变导致一例重排型肺腺癌患者疾病快速进展：病例报告
Transl Cancer Res. 2021 Jun;10(6):3081-3086. doi: 10.21037/tcr-20-3473.
3
Low expression of the ubiquitin ligase FBXW7 correlates with poor prognosis of patients with colorectal cancer.泛素连接酶FBXW7的低表达与结直肠癌患者的不良预后相关。
Int J Clin Exp Pathol. 2018 Jan 1;11(1):413-419. eCollection 2018.
4
FBXW7 in Cancer: What Has Been Unraveled Thus Far?癌症中的FBXW7：迄今为止已揭示了什么？
Cancers (Basel). 2019 Feb 19;11(2):246. doi: 10.3390/cancers11020246.
5
FBXW7 deletion contributes to lung tumor development and confers resistance to gefitinib therapy.FBXW7 缺失促进肺肿瘤的发展，并赋予对吉非替尼治疗的抗性。
Mol Oncol. 2018 Jun;12(6):883-895. doi: 10.1002/1878-0261.12200. Epub 2018 May 9.
6
Morphologic and molecular study of lung cancers associated with idiopathic pulmonary fibrosis and other pulmonary fibroses.与特发性肺纤维化及其他肺纤维化相关的肺癌的形态学和分子研究。
Respir Res. 2017 Jun 15;18(1):120. doi: 10.1186/s12931-017-0605-y.
7
The importance of regulatory ubiquitination in cancer and metastasis.调节性泛素化在癌症和转移中的重要性。
Cell Cycle. 2017 Apr 3;16(7):634-648. doi: 10.1080/15384101.2017.1288326. Epub 2017 Feb 6.
8
Towards standardization of next-generation sequencing of FFPE samples for clinical oncology: intrinsic obstacles and possible solutions.迈向临床肿瘤学中福尔马林固定石蜡包埋样本的下一代测序标准化：内在障碍与可能的解决方案。
J Transl Med. 2017 Jan 31;15(1):22. doi: 10.1186/s12967-017-1125-8.
9
Impact of genomic profiling on the treatment and outcomes of patients with advanced gastrointestinal malignancies.基因组分析对晚期胃肠道恶性肿瘤患者治疗及预后的影响
Cancer Med. 2017 Jan;6(1):195-206. doi: 10.1002/cam4.992. Epub 2016 Dec 28.
10
Fbxw7 Tumor Suppressor: A Vital Regulator Contributes to Human Tumorigenesis.Fbxw7肿瘤抑制因子：对人类肿瘤发生起重要作用的调节因子
Medicine (Baltimore). 2016 Feb;95(7):e2496. doi: 10.1097/MD.0000000000002496.
本文引用的文献
1
Personalized medicine in lung cancer: what we need to know.肺癌个体化医学：我们需要了解的内容。
Nat Rev Clin Oncol. 2011 Aug 23;8(11):661-8. doi: 10.1038/nrclinonc.2011.126.
2
FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.FBXW7靶向mTOR进行降解，并在肿瘤抑制中与PTEN协同作用。
Science. 2008 Sep 12;321(5895):1499-502. doi: 10.1126/science.1162981.
3
FBXW7/hCDC4 is a general tumor suppressor in human cancer.FBXW7/hCDC4是人类癌症中的一种通用肿瘤抑制因子。
Cancer Res. 2007 Oct 1;67(19):9006-12. doi: 10.1158/0008-5472.CAN-07-1320.
4
Somatic mutation of hCDC4 gene is rare in lung adenocarcinomas.hCDC4基因的体细胞突变在肺腺癌中较为罕见。
Acta Oncol. 2006;45(4):487-8. doi: 10.1080/02841860500400979.
5
Fbxw7/Cdc4 is a p53-dependent, haploinsufficient tumour suppressor gene.Fbxw7/Cdc4是一种p53依赖的、单倍体不足的肿瘤抑制基因。
Nature. 2004 Dec 9;432(7018):775-9. doi: 10.1038/nature03155.
Zotero 插件